Mucodel Pharma Completes Pilot Study of Buccal Naloxone

September 21, 2016
Pharmaceutical Technology Editors

Mucodel reported that the study met its objectives, and effectively delivered a dose of naloxone using an oromucosal route.

Mucodel Pharma announced the completion of a pilot study involving buccal naloxone, a product under development for the reversal of opioid overdose, the company said in a Sept. 21, 2016 press announcement. Exonal employs Mucodel’s Co-Gel platform for oromucosal delivery of pharmaceutically active agents. Mucodel reported that the study met its objectives and demonstrated that Exonal was able to rapidly deliver the naloxone dose.

Naloxone is an FDA approved agent that treats the effects of opioid overdose caused by the use or misuse of prescription and illicit opioids. There is currently no approved naloxone rescue product with an oromucusol route for administration. FDA formulations of rescue naloxone include injectable products and nasal sprays.

Source: Mucodel Pharma